News und Analysen
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Key Points
- Interested in Recursion Pharmaceuticals, Inc.? Here are five stocks we like better.
- AI platform and partnerships: Recursion has accumulated more than 50 petabytes of multimodal
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
Key Points
- Interested in PTC Therapeutics, Inc.? Here are five stocks we like better.
- PTC Therapeutics plans to acquire ST-920, a one-time Fabry disease gene therapy, through a competitive
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Key Points
- Interested in Pulse Biosciences, Inc? Here are five stocks we like better.
- Pulse Biosciences is advancing nanosecond pulsed field ablation (nsPFA) as a non-thermal platform for
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Key Points
- Interested in Ocugen, Inc.? Here are five stocks we like better.
- Ocugen is targeting 2027 BLA filings for its OCU400 retinitis pigmentosa and OCU410ST Stargardt disease gene
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
Key Points
- Interested in TuHURA Biosciences, Inc.? Here are five stocks we like better.
- TuHURA is advancing IFx into a Phase III trial with pembrolizumab as a first-line treatment for advanced
ImmuCell Q2 Earnings Call Highlights
Key Points
- Interested in ImmuCell Corporation? Here are five stocks we like better.
- Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million
Pelthos Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Pelthos Therapeutics Inc.? Here are five stocks we like better.
- ZELSUVMI momentum continued: Second-quarter net product revenue rose 45% sequentially to $15.4 million
JFrog Says AI Software Boom, Cloud Demand and Security Adoption Are Fueling Growth
Key Points
- Interested in JFrog Ltd.? Here are five stocks we like better.
- JFrog reported strong growth, including 29% overall revenue growth and 53% cloud-revenue growth, driven by higher
Lucid Diagnostics Q2 Earnings Call Highlights
Key Points
- Interested in Lucid Diagnostics Inc.? Here are five stocks we like better.
- Q2 revenue rose 17% sequentially to $1.5 million on 2,770 EsoGuard tests, although revenue recognition
Lumexa Imaging Q2 Earnings Call Highlights
Key Points
- Interested in Lumexa Imaging Holdings, Inc.? Here are five stocks we like better.
- Lumexa returned to profitability in Q2: Revenue rose 5.1% year over year to $264.2 million, net
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Key Points
- Interested in Candel Therapeutics, Inc.? Here are five stocks we like better.
- Candel Therapeutics plans to submit a biologics license application by the end of 2026 for aglatimagene
Roche Aktie: Kooperation mit ChemoMetec abgeschlossen
Roche stellt die Weichen für ein wachstumsstarkes zweites Halbjahr. Der Schweizer Gesundheitskonzern kombiniert operative…
Der Beitrag Roche Aktie: Kooperation mit ChemoMetec abgeschlossen erschien
C.H. Robinson to Appeal Dallas Verdict, Stands by Growth and Buyback Plans
Key Points
- Interested in C.H. Robinson Worldwide, Inc.? Here are five stocks we like better.
- C.H. Robinson plans to appeal a large Dallas jury verdict tied to a fatal accident, with the appeal
Stereotaxis Q2 Earnings Call Highlights
Key Points
- Interested in Stereotaxis Inc.? Here are five stocks we like better.
- Second-quarter revenue was $7.7 million, with recurring revenue rising to $6.2 million as catheter sales offset
Seer Q2 Earnings Call Highlights
Key Points
- Interested in Seer, Inc.? Here are five stocks we like better.
- Seer’s second-quarter revenue fell year over year to $3.1 million from $4.1 million, pressured by academic and
Spectral AI Q2 Earnings Call Highlights
Key Points
- Interested in Spectral AI, Inc.? Here are five stocks we like better.
- FDA clearance is shifting Spectral AI toward commercialization: The company plans a disciplined U.S. and
NORMA Group Q2 Earnings Call Highlights
Key Points
- Interested in NORMA Group SE? Here are five stocks we like better.
- Profitability improved despite weak automotive demand: Q2 adjusted EBIT rose to EUR 7.6 million from EUR 2.3
Cannae Q2 Earnings Call Highlights
Key Points
- Interested in Cannae Holdings, Inc.? Here are five stocks we like better.
- Cannae strengthened liquidity by selling its 49% stake in The Watkins Company for $90 million and
Life360 Q2 Earnings Call Highlights
Key Points
- Interested in Life360, Inc.? Here are five stocks we like better.
- Life360 delivered strong Q2 growth, with revenue up 38% to a record $159 million and monthly active users
Lundin Mining Q2 Earnings Call Highlights
Key Points
- Interested in Lundin Mining Co.? Here are five stocks we like better.
- Lundin Mining delivered strong Q2 results, with revenue above $1.2 billion, adjusted EBITDA of $658 million and
Knight Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Knight Therapeutics Inc.? Here are five stocks we like better.
- Record first-half performance: Knight Therapeutics reported CAD 293 million in revenue, CAD 52 million
Vaxart Q2 Earnings Call Highlights
Key Points
- Interested in Vaxart, Inc.? Here are five stocks we like better.
- Vaxart reported favorable 12-month safety data from its 400-person Phase II-B COVID-19 vaccine sentinel cohort, with
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better.
- Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and
Advanced Drainage Systems Q1 Earnings Call Highlights
Key Points
- Interested in Advanced Drainage Systems, Inc.? Here are five stocks we like better.
- Record first-quarter performance: Fiscal 2027 net sales reached $1 billion, up 21% year over
Smith & Nephew SNATS Q2 Earnings Call Highlights
Key Points
- Interested in Smith & Nephew SNATS, Inc.? Here are five stocks we like better.
- Smith & Nephew cut its 2026 underlying revenue-growth outlook to about 4% after second-quarter growth